Erratum für: Das klinische Ergebnis eines Therapiewechsels von Ranibizumab und/oder Bevacizumab zu Aflibercept bei neovaskulärer altersabhängiger Makuladegeneration (AMD) (Klinische Monatsblatter fur Augenheilkunde (2016) 233:8 (945-950) DOI: 10.1055/s-0042-101348);Correction for: Switching therapy from ranibizumab and/or bevacizumab to aflibercept in neovascular age-related macular degeneration (AMD): One-year results (Klinische Monatsblatter fur Augenheilkunde (2016) 233:8 (945-950) DOI: 10.1055/s-0042-101348);Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results;Das klinische Ergebnis eines Therapiewechsels von Ranibizumab und/oder Bevacizumab zu Aflibercept bei neovaskulärer altersabhängiger Makuladegeneration (AMD)

Klinische Monatsblatter fur Augenheilkunde

Volumn 233, Issue 8, 2016, Pages 945-950

  Pfau, M ^a   Fassnacht Riederle, H M ^b   Freiberg, F J ^b   Wons, J B ^b   Wirth, M ^b   Becker, M D ^b   Michels, S ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b TRIEMLI HOSPITAL   (Switzerland)

Author keywords

pathology; pharmacology; retina

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; AGED; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PROCEDURES; RISK FACTOR; SWITZERLAND; TREATMENT OUTCOME; UTILIZATION; VERY ELDERLY; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SWITZERLAND; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84964666692     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0042-115798     Document Type: Erratum

References (37)

1. Adamis A. P., Miller J. W., Bernal M. T. et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol: 1994; 118 445 450
2. Aiello L. P., Avery R. L., Arrigg P. G. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med: 1994; 331 1480 1487
3. Rosenfeld P. J., Brown D. M., Heier J. S. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med: 2006; 355 1419 1431
4. Brown D. M., Kaiser P. K., Michels M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med: 2006; 355 1432 1444
5. Chakravarthy U., Harding S. P., Rogers C. A. et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet: 2013; 382 1258 1267
6. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Martin D. F., Maguire M. G. et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology: 2012; 119 1388 1398
7. Berg K., Pedersen T. R., Sandvik L. et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology: 2015; 122 146 152
8. Lux A., Llacer H., Heussen F. M. et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol: 2007; 91 1318 1322
9. Krebs I., Glittenberg C., Ansari-Shahrezaei S. et al. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol: 2013; 97 1443 1446
10. Eghoj M. S., Sorensen T. L. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol: 2012; 96 21 23
11. Forooghian F., Chew E. Y., Meyerle C. B. et al. Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmol: 2011; 89 e206 e207
12. Brown D. M., Michels M., Kaiser P. K. et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology: 2009; 116 57 65 e5
13. Ferrara N., Damico L., Shams N. et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina: 2006; 26 859 870
14. Leveziel N., Pelat T., Watier H. et al. Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration. Ophthalmologica: 2014; 232 53 56
15. Moja L., Lucenteforte E., Kwag K. H. et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev: 2014; 9 CD011230
16. Fassnacht-Riederle H., Becker M., Graf N. et al. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol: 2014; 252 1705 1709
17. Gasperini J. L., Fawzi A. A., Khondkaryan A. et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol: 2012; 96 14 20
18. Meyer C. H., Krohne T. U., Holz F. G. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina: 2011; 31 1877 1884
19. Stewart M. W., Rosenfeld P. J. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol: 2008; 92 667 668
20. Yang L. P., McKeage K. Intravitreal aflibercept (Eylea(®)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion. Drugs Aging: 2014; 31 395 404
21. Zhang F., Tang Z., Hou X. et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA: 2009; 106 6152 6157
22. Rakic J. M., Lambert V., Devy L. et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci: 2003; 44 3186 3193
23. Stewart M. W. Predicted biologic activity of intravitreal bevacizumab. Retina: 2007; 27 1196 1200
24. Spaide R. F. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol: 2009; 148 1 3
25. Toalster N., Russell M., Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina: 2013; 33 1351 1358
26. Lalwani G. A., Rosenfeld P. J., Fung A. E. et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol: 2009; 148 43 58 e41
27. Engelbert M., Zweifel S. A., Freund K. B. Treat and extend dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina: 2009; 29 1424 1431
28. Gregori N. Z., Feuer W., Rosenfeld P. J. Novel method for analyzing snellen visual acuity measurements. Retina: 2010; 30 1046 1050
29. Spaide R. F., Curcio C. A. Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina: 2011; 31 1609 1619
30. Fassnacht-Riederle H., Becker M., Graf N. et al. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol: 2014; 252 1705 1709
31. Heussen F. M., Shao Q., Ouyang Y. et al. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol: 2014; 252 909 915
32. Kumar N., Marsiglia M., Mrejen S. et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina: 2013; 33 1605 1612
33. Broadhead G. K., Hong T., Zhu M. et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina: 2015; 35 975 981
34. Mazaraki K., Fassnacht-Riederle H., Blum R. et al. Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration. Br J Ophthalmol: 2015; 99 1341 1344
35. Grunwald J. E., Daniel E., Huang J. et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology: 2014; 121 150 161
36. Ho A. C., Busbee B. G., Regillo C. D. et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology: 2014; 121 2181 2192
37. Heier J. S., Brown D. M., Chong V. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology: 2012; 119 2537 2548